• Telepathology: the remote review of pathology cases in real time, especially valuable for hospitals in rural or underserved areas.
• AI-assisted diagnostics: software tools that help identify patterns or anomalies in tissue samples, aiding pathologists in making more accurate and consistent diagnoses.
• Digital archiving: storing vast amounts of data securely and efficiently without the physical space constraints of traditional slide storage.

Epigenetic biomarkers are measurable changes to gene expression or chromatin structure that do not involve alteration of the DNA sequence itself. Unlike genetic mutations, which are permanent changes to the genome, epigenetic modifications can be dynamic and reversible. This makes them particularly intriguing for cancer research and therapeutics. The most common types of epigenetic changes include:

• DNA Methylation: The addition of methyl groups to DNA, typically at cytosine-phosphate-guanine (CpG) sites. In many cancers, hypermethylation of tumor suppressor genes leads to their silencing, while hypomethylation can activate oncogenes.
• Histone Modifications: Chemical changes to the proteins around which DNA is wound, affecting how tightly or loosely genes are packaged and thus their accessibility for transcription. 
• Non-coding RNAs: These RNA molecules don’t code for proteins but regulate gene expression post-transcriptionally.

When these epigenetic alterations occur consistently in cancer cells, but not in normal tissues, they become valuable epigenetic biomarkers and diagnostic tools.

To understand epigenetic modifications, it helps to start with a basic premise: every cell in the body contains the same DNA, yet not all genes are active in every cell. Why? Gene expression is tightly regulated by factors beyond the DNA sequence itself. These factors, which influence how and when genes are turned on or off, are known as epigenetic mechanisms.

In simple terms, epigenetic modifications are chemical changes to the DNA molecule or the proteins surrounding DNA (called histones) that affect gene activity without altering the actual genetic code. These modifications can either activate or silence genes and are crucial in cell differentiation, development, and response to environmental changes.

The most common epigenetic modification examples include: 

• DNA Methylation: The addition of a methyl group to DNA, typically at cytosine bases. This often suppresses gene expression.
• Histone Modification: Includes acetylation, methylation, phosphorylation, and ubiquitination of histone proteins, which affect how tightly DNA is wound and how accessible it is for transcription.
• Non-coding RNA: While not a chemical modification per se, non-coding RNAs can regulate gene expression post-transcriptionally and interact with other epigenetic systems. 

These changes are dynamic and reversible, making them a promising target for therapeutic intervention in diseases like cancer, autoimmune disorders, and neurological conditions.

Next-generation sequencing refers to a suite of technologies that allow for the high-throughput analysis of DNA and RNA. Unlike traditional Sanger sequencing, which sequences DNA one fragment at a time, next-generation DNA sequencing can process millions of fragments simultaneously. This allows researchers to gain a comprehensive view of genetic material more efficiently, accurately, and affordably than ever before. 

The technology has made it possible to perform complex tasks like whole genome sequencing—analyzing an organism’s entire DNA sequence in one go—and transcriptomic analysis, which reveals how genes are expressed across different tissues and conditions.

In practical terms, NGS has become essential in fields like oncology, pathology, infectious disease, and pharmacogenomics. However, its power increases exponentially when paired with the vast repositories of FFPE tissue samples collected in clinical settings.

The tumor microenvironment refers to a complex ecosystem of cells and extracellular matrix (ECM) surrounding a tumor. It is a constantly evolving entity, including various cellular components, such as immune cells, endothelial cells, pericytes, and fibroblasts, and non-cellular elements like signaling molecules or blood vessels. These components don’t only exist outside the tumor; they actively influence its behavior.

According to Sammy Ferri-Borgogno, Ph.D., instructor in Gynecologic Oncology, the tumor microenvironment can be compared to a yard and neighborhood, “You can think of the tumor as a house and the microenvironment as its yard and its neighborhood. The house is surrounded by a little ecosystem, and whatever happens in that yard or neighborhood impacts the house. Similarly, what happens in the house impacts the yard.” For example, the house will flood if the yard doesn’t properly drain after a heavy rainstorm. In cancer, when a tumor cell grows uncontrollably, it utilizes the microenvironment to grow exponentially faster and spread, creating more tumors. 

The TME contributes to tumor growth, angiogenesis, immune suppression, and metastasis. It also modulates how tumors respond—or don’t respond—to therapy. As a result, TME profiling is becoming essential in basic cancer research and clinical oncology.

Protein expression refers to the process by which proteins are synthesized, modified, and regulated within living organisms. It begins at the genetic level with gene expression, where DNA is transcribed into messenger RNA (mRNA). The mRNA is then translated by ribosomes to produce specific proteins.

These proteins are the workhorses of the cell, responsible for catalyzing biochemical reactions, providing structural support, regulating cell communication, and defending against pathogens. Any abnormalities in this process can lead to serious health conditions, including cancer, autoimmune diseases, and neurodegenerative disorders.

When you analyze FFPE samples, you’re essentially looking at a snapshot of this biological process frozen in time. The key is to retrieve and interpret the data accurately despite the challenges of fixation and long-term storage.

Cancer biomarkers are substances found in blood, tissue, or other body fluids that indicate cancer activity. Some biomarkers are produced by cancer cells, while others are the body’s response to the disease. Their presence gives doctors important clues about cancer type, stage, and treatment response.

In cancer diagnosis, biomarkers support early detection and differentiate between malignant and normal tissue. They also predict how aggressive a tumor might be. Modern oncology relies on biomarkers to personalize treatment. With the right biomarker, patients can avoid unnecessary treatments and receive the one most likely to be effective.

Biomarkers also help monitor recurrence, offering a non-invasive way to detect cancer remission. Despite their value, not all biomarkers are reliable alone. Doctors often combine cancer biomarker testing with imaging and other diagnostic procedures for accuracy.

For instance, combining Alpha-fetoprotein (AFP) detection with circulating free DNA (cfDNA) analysis increases the specificity of hepatocellular carcinoma (HCC) diagnosis to 94.4%, offering greater sensitivity and stronger clinical correlation compared to AFP alone.

A biomarker is a measurable biological characteristic that indicates disease risk, treatment response, or progression. There are several types of biomarkers, including diagnostic, monitoring, predictive, prognostic, and more. In modern medicine, professionals utilize analytical technology to measure a large number of biomarkers present in the human organism (in urine, hair, blood, tissues, etc.). 

There are several steps included in biomarker discovery and validation:

1. Identification: Researchers collect biological samples (e.g., blood, tissue, urine) and use techniques like genomics, proteomics, or metabolomics to identify potential biomarkers.
2. Validation: The identified biomarkers are tested in different sample sets to confirm their reliability and consistency.
3. Qualification: The biomarkers are evaluated in clinical studies to determine their relevance to a disease or condition.

Regulatory Approval & Implementation: If successful, the biomarker undergoes regulatory review and can be used in diagnostics, treatment monitoring, or drug development.

Several nucleic extraction methods are employed to obtain usable DNA and RNA from FFPE samples. The choice of method depends on the type of nucleic acid required and the intended downstream application, such as sequencing, PCR, or biomarker analysis. Each technique has its own advantages and limitations, making it essential to select the most suitable approach for optimal nucleic acid recovery.

1. Organic Solvent-Based Extraction

This method utilizes phenol-chloroform for phase separation of nucleic acids from proteins and lipids. While it is effective in extracting high-yield DNA, it involves toxic reagents and labor-intensive steps, making it less desirable for routine clinical applications. The process requires careful handling due to the hazardous nature of phenol and chloroform, both of which can cause skin irritation and require specialized waste disposal. Despite these challenges, solvent-based extraction remains a viable option for researchers needing high-purity DNA with minimal protein contamination. 

2. Silica Column-Based Extraction

SIlica column-based kits are widely used for FFPE samples as they provide a simple and effective way to purify DNA or RNA. These kits typically involve tissue deparaffinization, protease digestion, and nucleic acid binding to a silica membrane, followed by washing and elution. One of the key benefits of this method is its compatibility with automated platforms, making it suitable for high-throughput applications. Additionally, silica columns help remove inhibitors that could interfere with downstream molecular assays, ensuring reliable results in PCR and sequencing-based studies. 

3. Magnetic Bead-Based Extraction

This nucleic acid extraction method is a modern and automation-friendly route that ensures higher recovery of nucleic acids while minimizing contamination. The beads selectively bind nucleic acids, allowing for efficient purification with minimal loss. This method is particularly advantageous for laboratories that require rapid processing with high reproducibility. Since magnetic beads eliminate the need for centrifugation, they also reduce sample degradation and improve workflow efficiency. Furthermore, magnetic bead-based extraction provides excellent scalability, making it an ideal choice for both small research labs and large clinical diagnostic centers.

4. Enzyme Digestion Methods

Enzyme digestion techniques incorporate proteinase K or heat-based reversal of formaldehyde crosslinks to improve nuclein acid integrity. DNase treatment may also be included in RNA extraction protocols to remove contaminating genomic DNA, ensuring high-purity RNA for gene expression analysis. Enzymatic approaches are particularly useful for heavily degraded FFPE samples, as they help recover fragmented nucleic acids with improved quality. The effectiveness of these methods depends on optimizing digestion times and temperatures to maximize acid yield while preventing excessive degradation. By fine-tuning enzymatic parameters, researchers can enhance nucleic acid recovery from even the most challenging FFPE specimens.

A primary antibody is the first antibody introduced in an IHC experiment. It is designed to bind specifically to the target antigen in the tissue sample. These antibodies are typically generated in host species such as mice, rabbits, or goats and can be either monoclonal or polyclonal. Monoclonal primary antibodies recognize a single epitope on the antigen, providing high specificity, while polyclonal antibodies recognize multiple epitopes, increasing sensitivity.

Since the primary antibody directly binds to the antigen of interest, selecting one with high specificity and minimal cross-reactivity is essential. Researchers should consider factors such as host species, isotype, and antigen affinity to optimize detection. The isotype of a primary antibody refers to the class of immunoglobulin (lg) it belongs to, such as IgG, IgA, or IgM. These isotypes influence how the antibody interacts with secondary antibodies, which are used for signal amplification.